> > >

Meet Vaughn

Vaughn was diagnosed with mild hemophilia A at 18 months old. Growing up, his energetic and curious personality was a challenge because hemophilia limited his activities and left him feeling like he was “bubble-wrapped”.  Hemophilia treatment was different when Vaughn was young and his treatments often took 8 hours a day at the hospital. As a teenager, he contracted HIV from contaminated products and was told he had less than 2 years to live.  Although initially shaken by this news, Vaughn is not one to quit and now has his conditions under control.  As an adult, Vaughn is passionate about staying fit through diet and exercise as well as sharing his story with the world.  He also values a treatment that he can take with him as he lives his life.

Please see full Prescribing Information.

Individual results may vary.

Play
Pause
Skip
Volume
Chapters
Transcript
References
video_su
Fullscreen

Meet Vaughn

Chapters
Transcript
References

Vaughn was diagnosed with mild hemophilia A at 18 months old. Growing up, his energetic and curious personality was a challenge because hemophilia limited his activities and left him feeling like he was “bubble-wrapped”.  Hemophilia treatment was different when Vaughn was young and his treatments often took 8 hours a day at the hospital. As a teenager, he contracted HIV from contaminated products and was told he had less than 2 years to live.  Although initially shaken by this news, Vaughn is not one to quit and now has his conditions under control.  As an adult, Vaughn is passionate about staying fit through diet and exercise as well as sharing his story with the world.  He also values a treatment that he can take with him as he lives his life.

Please see full Prescribing Information.

Individual results may vary.

Return to overview

Chapters

Return to overview

Transcripts

Return to overview

References


Related Videos

Team Novo8™ logo


Team Novo8™ is a group of patients who switched to Novoeight® and spend their time helping others with hemophilia A. Hear more about their mission, and how your patients may benefit from their experiences.
 

Meet Team Novo8™

The National Hemophilia Foundation Playing It Safe: Bleeding Disorders, Sports and Exercise guide provides information on sports and activities and how your patients participate safely in physical activities.

Also available from Novo Nordisk:

NovoSeven® RT Logo

Visit website  | Prescribing Information

Esperoct® Logo

Visit website | Prescribing Information

Tretten® Logo

Visit website | Prescribing Information

Rebinyn® Logo

Visit website  | Prescribing Information

Selected Important Safety Information

Contraindications

  • Do not use in patients who have had life-threatening hypersensitivity reactions, including anaphylaxis, to Novoeight® or its components, including hamster proteins

Warnings and Precautions

  • Anaphylaxis and severe hypersensitivity reactions are possible. Patients may develop hypersensitivity to hamster proteins, which are present in trace amounts in the product. Should symptoms occur, discontinue Novoeight® and administer appropriate treatment

Indications and Usage

Novoeight® (antihemophilic factor, recombinant) is indicated for use in adults and children with hemophilia A for on-demand treatment and control of bleeding episodes, perioperative management, and routine prophylaxis to reduce the frequency of bleeding episodes.

  • Novoeight® is not indicated for the treatment of von Willebrand disease

Important Safety Information

Contraindications

  • Do not use in patients who have had life-threatening hypersensitivity reactions, including anaphylaxis, to Novoeight® or its components, including hamster proteins

Warnings and Precautions

  • Anaphylaxis and severe hypersensitivity reactions are possible. Patients may develop hypersensitivity to hamster proteins, which are present in trace amounts in the product. Should symptoms occur, discontinue Novoeight® and administer appropriate treatment
  • Development of activity-neutralizing antibodies (inhibitors) may occur. Previously untreated patients (PUPs) are at greatest risk for inhibitor development with all factor VIII products. Inhibitors have been reported following administration of Novoeight in PUPs. If expected plasma factor VIII activity levels are not attained, or if bleeding is not controlled with an appropriate dose, perform testing for factor VIII inhibitors

Adverse Reactions

  • The most frequently reported adverse reactions (≥1%) were inhibitors in Previously Untreated Patients (PUPs), injection site reactions, and pyrexia.

Please click here for Prescribing Information